Agios Pharmaceuticals' stock soared 9.68% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.

The biopharmaceutical company reported quarterly revenue of $20.75 million, more than doubling from the $8.73 million reported in the same period last year and beating the average analyst estimate of approximately $13.65 million by a wide margin. The strong performance was primarily driven by the successful U.S. commercial launch of its drug AQVESME (mitapivat) for thalassemia in late January 2026, along with continued international demand for PYRUKYND.

While the company's net loss widened year-over-year to $99.11 million, reflecting higher research & development and commercial expenses related to the AQVESME launch, investors focused on the substantial revenue beat and positive business updates. The company also advanced its mitapivat sickle cell disease program toward a planned supplemental New Drug Application submission in the second quarter of 2026.